Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study

• DOI: 10.4193/rhin23.335
• Publication Date: 2024-04-15T14:57:41Z
• Authors: A R Sedaghat; W J Fokkens; V J Lund; P W Hellings; R C Kern; S Reitsma; S Toppila-Salmi; M Bernal- Sprekelsen; J Mullol; P Gevaert; T Teeling; I Alobid; W T Anselmo-Lima; F M Baroody; A Cervin; N A Cohen; J Constantinidis; L De Gabory; M Desrosiers; R J Harvey; L Kalogjera; A Knill; B N Landis; C Meco; C M Philpott; D Ryan; R J Schlosser; B A Senior; T L Smith; P V Tomazic; L Zhang; C Hopkins
• Keywords: Chronic Rhinosinusitis; Delphi Method; Delphi

Chronic rhinosinusitis (CRS) disease control is a global metric of status for CRS. While there broad acceptance that it an important treatment goal, has been inconsistency in the criteria used to define CRS control. The objective this study was identify and develop consensus around essential assessment control.Modified Delphi methodology consisting three rounds review list 24 possible developed by 12-person steering committee. core authorship multidisciplinary EPOS 2020 guidelines invited participate.Thirty-two individuals accepted invitation participate no dropout participants throughout entire (3 rounds). Consensus were: overall symptom severity, need CRS-related systemic corticosteroids prior 6 months, severity nasal obstruction, patient-reported Near-consensus items endoscopy findings, smell loss, quality life, impairment normal activities discharge. Participants’ comments provided insights into caveats of, disagreements related to, near-consensus items.Overall use corticosteroids, are widely agreed upon Consideration assess should be implemented with their intrinsic mind. These identified criteria, together evidence-based support, will provide foundation which wide-spread can developed.